Transcription factor paired related homeobox 1 (PRRX1) activates matrix metalloproteinases (MMP)13, which promotes the dextran sulfate sodium-induced inflammation and barrier dysfunction of NCM460 cells

Xiujing Zhang, Lizhuan Ma, Ying Shen, Chao Zhang, Bingxu Hou, and Yanli Zhou

Division of Gastroenterology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China; Department of Endoscopic Therapy, Tangshan People’s Hospital, Tangshan, Hebei, China

ABSTRACT

Paired related homeobox 1 (PRRX1) is a newly identified transcription factor that regulates the expression of various genes. We aimed to investigate the roles of PRRX1 and Matrix metalloproteinases (MMP)13 in dextran sulfate sodium (DSS)-induced inflammation and barrier dysfunction of NCM460 cells. PRRX1 expression in the mucosal tissues of patients with ulcerative colitis was analyzed using the GSE87466 microarray. PRRX1 and MMP13 expression was examined using Western blotting and RT-qPCR following the exposure of the NCM460 cells to DSS. The JASPAR database was used to predict the binding sites of PRRX1 to the MMP13 promoter, which was verified by luciferase reporter and chromatin immunoprecipitation assays. MMP13 expression was then detected following PRRX1 silencing or overexpression. The levels of inflammatory factors were determined using ELISA. Finally, the expression of intestinal barrier function-related proteins was evaluated using Western blotting and cellular permeability was detected by Transepithelial electrical resistance. PRRX1 was upregulated in the mucosal tissue samples of patients with UC. DSS induction upregulated PRRX1 and MMP13 expression. PRRX1 bound to the promoter of MMP13, which was further supported by the decreased expression of MMP13 observed following PRRX1 knockdown and its increased expression following PRRX1 overexpression. Furthermore, PRRX1 deletion decreased TNF-α, IL-1β and IL-6 levels in the DSS-challenged NCM460 cells, which were subjected to MMP13 overexpression. Moreover, PRRX1 silencing upregulated ZO-1, occludin and claudin-1 expression and elevated the TEER value, whereas MMP13 overexpression attenuated these effects. Collectively, PRRX1 activates MMP13, which in turn promotes the DSS-induced inflammation and barrier dysfunction of NCM460 cells.

Introduction

Inflammatory bowel disease (IBD) is regarded as a chronic relapsing inflammatory disorder, which can affect almost the entire gastrointestinal tract [1,2]. Based on clinical and pathologic patterns, IBD has two main manifestation, Crohn’s disease and ulcerative colitis (UC), which are triggered by uncontrolled gastrointestinal inflammation and epithelial injury [3]. IBD usually occurs in young adults and is related to inheritance, infection, immune function and environmental factors [4]. IBD has attracted widespread attention and research interests due to its increasing incidence worldwide over the past few years. It also has a significant effect on morbidity and the quality of life of affected individuals [5,6]. Therefore, it is of utmost importance to acquire an enhanced understanding of the pathogenesis underlying IBD in order to identify and develop more effective therapeutic targets for the early prevention and treatment of this disease.

Elevated levels of inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-6 and IL-1β, have been observed in active IBD and are related to the severity of inflammation [7]. Additionally, Zonula occludens-1 (ZO-1), occludin and claudin-1 are three crucial tight junction proteins, which play significant roles in the maintenance of the physiological function of the intestinal barrier [8]. Matrix metalloproteinases (MMPs) are a group of proteolytic
enzymes that can participate in tissue damage and repair during the process of inflammation. There is substantial evidence to suggest that MMPs play significant roles in the occurrence of IBD, the formation of intestinal mucosal damage, the destruction of submucosal matrix and in carcinogenesis [9]. MMP13 (also known as collagenase-3) is a member of a large family of zinc-dependent neutral endopeptidases [10]. It has been demonstrated that MMP13 expression is significantly elevated in the mucosal samples of patients with IBD, and a positive correlation has been found between MMP13 and histological inflammation scores in mucosal tissues [11]. Another study suggested that MMP13 regulates the barrier function of the intestinal mucosal epithelium by activating TNF-α. Therefore, MMP13-mediated inflammation-related pathways play a crucial role in the integrity of the intestinal mucosal epithelial barrier. Paired related homeobox 1 (PRRX1) is a newly identified transcription factor that modulates the expression of a variety of genes involved in multiple pathological processes, such as development, tumorigenesis and inflammation [12–14]. Therefore, the present study aimed to investigate the expression of PRRX1 and MMP13 and their roles in the development of IBD by using a sulfate sodium (DSS)-induced human colon mucosal epithelial cell model.

In the present study, the DSS-challenged human colon mucosal epithelial cell line, NCM460, was used to simulate the in vitro model of IBD. In addition, the effects of MMP13 on the inflammation and barrier dysfunction of NCM460 cells, as well as the regulatory mechanisms of PRRX1 and MMP13 involved in this process were explored. The findings of the present study may provide new insight into IBD development and may aid in the development of novel treatment strategies for this disease.

Materials and methods

Bioinformatics analyses

The expression of PRRX1 in UC tissues and normal tissues was analyzed using TNMplot database [15]. The GSE dataset GSE87466 consisting of 108 samples (87 UC and 21 normal) was downloaded from the GEO database and analyzed using GEO2R. The potential transcription factor binding sites in the promoter of MMP13 and PRRX1 were predicted by JASPAR (http://jaspar.genereg.net/) database.

Cell culture and treatment

NCM460 cells were purchased from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. The cells were cultured in a humidified cell incubator (5% CO₂, 37°C) with Dulbecco’s modified Eagle medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.). DSS (35–45 kDa) at 0.8 μg/ml was used to stimulate the NCM460 cells for 12 h at 37°C according to the previous study [16].

Cell transfection

For transfection, NCM460 cells in the logarithmic growth phase were plated into 24-well plates at a density of 2 × 10⁵ cells/well. The PRRX1 pcDNA3.1 plasmid (Ov-PRRX1), MMP13 pcDNA3.1 plasmid (Ov-MMP13), the empty plasmid (Ov-NC), small interfering RNA (siRNA/si) targeting PRRX1 [si-PRRX1#1 (5’-GGACAATG ACCAGCTGAACTCAGA-3’) and si-PRRX1#2 (5’-CAATGACAGCTGAACTCAGAAGAA-3’)] and the negative control (si-NC; 5’-GGAGTACCCAGGATCTCAACCAGAAGAA-3’) were obtained from Shanghai GenePharma Co., Ltd. Transfection experiments were performed using the transfection reagent, Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.), as per the manufacturer’s instructions. Following 48 h of transfection, the cells were harvested and the expression of the aforementioned genes was examined using reverse transcription-quantitative PCR (RT-qPCR) and Western blot analysis.

Determination of the levels of inflammatory factors

Enzyme-linked immunosorbent assay (ELISA) kits were utilized for the determination of inflammatory factors including TNF-α, IL-1β and IL-6 in
the cell supernatants from the different groups. The testing experiments were conducted strictly following the instructions of the manufacturer of the kits (Shanghai XiTang Biotechnology). The absorbance was read at a wavelength of 450 nm using a plate reader (BioTek Instruments, Inc.).

**Transepithelial electrical resistance (TEER) measurement**

For cellular permeability studies, the NCM460 cells were seeded in 24-well transwell plates, on polyester membrane filters (pore size 0.4 μM). The complete medium was added to both the apical and the basal chamber and the complete medium was changed every other day. After formatting a complete monolayer, the TEER was measured by using an epithelial Millicell ERS-2 Voltohmeter (Millipore; Bedford, MA, USA). The measured resistance value was multiplied by the area of the filter to obtain an absolute value of TEER, expressed as Ωcm2 [17].

**Dual luciferase reporter assay**

Luciferase reporter plasmids (Promega Corporation) were constructed with the wild-type (WT) and mutant-type regions of the MMP13 promoter. The luciferase reporter plasmids and PRRX1-expressing plasmid were co-transfected into the NCM460 cells using Lipofectamine 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Luciferase activities were measured at 48 h following transfection using the Dual Luciferase Reporter assay kit (Promega Corporation) [18]. The luciferase activities were normalized to Renilla luciferase activity.

**Chromatin immunoprecipitation (ChIP) assay**

The binding of PRRX1 to the MMP13 promoter was examined using a ChIP assay kit (Beyotime Institute of Biotechnology) according to the standard protocol [19]. The NCM460 cells were cross-linked with 1% formaldehyde for 15 min, and the cell lysates in lysis buffer were sonicated to achieve chromatin fragments. ChIP was conducted following incubation with anti-PRRX1 and IgG (negative control) antibodies. The enrichment of indicated proteins in the MMP13 promoter was evaluated using RT-qPCR.

**RT-qPCR**

Total RNA was isolated from the NCM460 cells using TRIzol* reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and then reverse transcribed into complementary DNA (cDNA) using a Superscript III kit (Invitrogen; Thermo Fisher Scientific, Inc.). PCR experiments were then performed using SYBR-Green PCR Master mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) on an ABI 7300 thermal-recycler (Applied Biosystems; Thermo Fisher Scientific, Inc.). The following thermocycling conditions were used: Initial denaturation at 95°C for 10 min; followed by 40 cycles of denaturation at 95°C for 15 sec and annealing at 60°C for 1 min; and a final extension of 10 min at 72°C. The following primer sequences were used for qPCR: PRRX1 forward, 5'-CAGGCAGATGAGAAGCTTG-3' and reverse, 5'-AAAACATCAAGGATGTGTCG-3'; MMP13 forward, 5'-TCCTGATGTTGGTGAATACAGT-3' and reverse, 5'-GCCATCGTGAAGTCTGTTAAAT-3'; ZO-1 forward, 5'-CAACATACAGTGACGCTTCAAC-3' and reverse, 5'-CACATTGAGTTTCCCACCTC-3'; occludin forward, 5'-CGGCCAGCTCTGATGAG-3' and reverse, 5'-TCTGTATTCTCTGTAGGCCAGT-3' claudin-1 forward, 5'-AAATCGAAACTTGGAGGCC-3' and reverse, 5'-AACAAAGATGCTATGGGTGTC-3'; β-actin forward, 5'-TAGTTGCGTTACCCCTTTC-3' and reverse, 5'-TGCACCTTCACCCTCC-3'. ß-actin gene was used as an endogenous control. The expression of each target gene was calculated relative to the control using the 2^ΔΔCq method [20].

**Western blot analysis**

Cells were lysed in lysis buffer (Beyotime Institute of Biotechnology) to collect whole cell extracts. The protein contents were quantified using a bicinchoninic acid (BCA) kit (Beyotime Institute of Biotechnology). Subsequently, equal amounts of proteins (40 μg protein/lane) were resolved on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. Possible nonspecific binding was blocked using
5% nonfat milk at room temperature for 2 h and then incubated overnight at 4°C with specific primary antibodies. The horseradish peroxidase (HRP)-coupled secondary antibody was then added and incubated for 1.5 h at room temperature. The resulting bands were visualized under enhanced chemiluminescence (MilliporeSigma). Band densities of target proteins were normalized to those of glyceraldehyde-phosphate dehydrogenase (GAPDH) and semi-quantified using ImageJ software (version 1.52 r; National Institutes of Health).

**Statistical analysis**

Quantitative data are presented as the mean ± standard deviation (SD) of three independent experiments. Analysis and graphing were performed using GraphPad Prism 8.0 (GraphPad Software, Inc.). Statistical comparisons were evaluated using an unpaired t-test or one-way analysis of variance (ANOVA) with Tukey’s post hoc test. P < 0.05 was considered to indicate a statistically significant difference.

**Results**

**PRRX1 and MMP13 expression is upregulated in DSS-stimulated NCM460 cells**

PRRX1 is a newly identified transcription factor that modulates the expression of a variety of genes involved in pathological processes and MMP13 expression is significantly elevated in the mucosal samples of patients with IBD [11,14]. The roles and regulatory mechanisms of PRRX1 and MMP13 in DSS-challenged human colon mucosal epithelial cells were explored in this study. Firstly, Western blot analysis and RT-qPCR were used to evaluate the expression levels of PRRX1 and MMP13 in the NCM460 cells following exposure to DSS. As displayed in Figure 1(a), PRRX1 and MMP13 protein expression was upregulated following DSS induction compared with the untreated NCM460 cells. Consistently, DSS led to elevated PRRX1 and MMP13 mRNA expression levels relative to the control group Figure 1(b). These results indicated the abnormally high expression of PRRX1 and MMP13 in DSS-stimulated NCM460 cells.

**PRRX1 can directly bind to the MMP13 promoter in DSS-stimulated NCM460 cells**

To explore the possible regulatory mechanisms of between PRRX1 and MMP13 in DSS-induced NCM460 cells, the JASPAR database predicted that PRRX1 could directly bind to the MMP13 promoter Figure 2(a). Additionally, in the GSE87466 microarray (including 87 samples of UC and 21 normal samples), it was found that PRRX1 was highly expressed in the mucosal tissue samples of patients with UC Figure 2(b). Following transfection with Ov-PRRX1, PRRX1 was overexpressed at the

![Figure 1](image1.png)  
**Figure 1.** PRRX1 and MMP13 expression is upregulated in DSS-stimulated NCM460 cells. (a) Western blot analysis was used to assess the protein expression levels of PRRX1 and MMP13. (b) Measurement of PRRX1 and MMP13 mRNA expression levels using RT-qPCR assay. **P < 0.01 and ***P < 0.001. PRRX1, paired related homebox 1.
transcriptional and post-transcriptional level as compared with the empty vector group Figure 2(c, d). Additionally, PRRX1 protein and mRNA expression was significantly decreased in the si-PRRX1#1 and si-PRRX1#2 groups when compared with the si-NC group, and a lower PRRX1 expression

Figure 2. PRRX1 can directly bind to the MMP13 promoter in DSS-stimulated NCM460 cells. (a) The binding site of PRRX1 to the MMP13 promoter was predicted using the JASPAR database. (b) The expression of PRRX1 in the mucosal tissues of patients with UC was analyzed using the GSE87466 microarray (including 87 samples of UC and 21 normal samples). (c and d) Western blot analysis and RT-qPCR were utilized for the measurement of PRRX1 expression following transfection of the cells with Ov-PRRX1 and si-PRRX1. (e and f) The interaction between PRRX1 and MMP13 was determined using dual-luciferase reporter and chromatin immunoprecipitation assays. (g and h) The expression of MMP13 was examined using Western blot analysis and RT-qPCR.

*P < 0.05, **P < 0.01 and ***P < 0.001. PRRX1, paired related homeobox 1; UC, ulcerative colitis; RT-qPCR, reverse transcription-quantitative PCR; MMP, Matrix metalloproteinase; Ov, overexpression; si, small interfering RNA; WT, wild-type; MUT, mutant-type; S1, site1; S2, site2.
was observed in the si-PRRX1#2 group Figure 2(c,d); thus, si-PRRX1#2 was selected for use in further experiments.

The results of luciferase reporter assays presented in Figure 2(e) indicated that the luciferase activity was increased in the NCM460 cells co-transfected with WT (S1) and Ov-PRRX1 compared with the Ov-NC group. By contrast, no significant difference was observed between Ov-PRRX1 and Ov-NC in the WT (S2) group. Moreover, the enrichment of MMP13 was elevated in the S1 group following incubation with PRRX1 relative to the IgG Figure 2(f). Additionally, PRRX1 silencing decreased the expression level of MMP13, whereas PRRX1 overexpression increased MMP13 expression in NCM460 cells Figure 2(g,h). These data provide evidence that PRRX1 can directly bind to the MMP13 promoter and regulate its expression.

**MMP13 overexpression attenuates the inhibitory effects of PRRX1 knockdown on the DSS-induced inflammation of NCM460 cells**

Subsequently, to validate our hypothesis that transcription factor PRRX1-mediated MMP13 upregulation promotes DSS-induced inflammation and barrier dysfunction of NCM460 cells, MMP13 was overexpressed by transfection with a MMP13 pcDNA3.1 plasmid. MMP13 expression was increased compared with the empty vector group Figure 3(a,b). Moreover, the levels of inflammation-related factors were evaluated using ELISA kits. As illustrated in Figure 3(c-e), DSS exposure increased the levels of TNF-α, IL-1β and IL-6 compared with the control group; these levels were decreased following the loss-of-function of PRRX1. Of note, MMP13 overexpression reversed the inhibitory effects of PRRX1 silencing on the levels of the aforementioned inflammatory factors. These observations indicated that the PRRX1-induced activation of MMP13 promoted the DSS-induced inflammation of NCM460 cells.

**MMP13 overexpression attenuates the suppressive effects of PRRX1 knockdown on the barrier dysfunction of NCM460 cells challenged with DSS**

Finally, to evaluate the effects of PRRX1 and MMP13 on the DSS-induced barrier dysfunction of NCM460 cells, Western blot analysis and RT-qPCR were employed to detect the expression of
Zonula ZO-1, occludin and claudin-1. A significant decrease in ZO-1, occludin and claudin-1 expression was observed following DSS stimulation when compared with the control group; these levels were upregulated following transfection with si-PRRX1#2 Figure 4(a,b). By contrast, MMP13 overexpression partially alleviated the promoting effects of PRRX1 knockdown on the expression of ZO-1, occludin and claudin-1. Besides, the protein expression levels of ZO-1, occludin and claudin-1 were increased in the DSS+si-PRRX1#2+ Ov-MMP13 group when compared to the DSS group. However, only claudin-1 mRNA expression presented a significant difference in the DSS+si-PRRX1#2+ Ov-MMP13 group relative to the DSS group. Consistently, compared with the control group, the TEER value in the DSS group was significantly decreased Figure 4(c). After transfection with si-PRRX1#2, the TEER value was elevated relative to the DSS group, which was reversed following the further MMP13 overexpression. Overall, these data suggest that the PRRX1-induced activation of MMP13 aggravates the barrier dysfunction of NCM460 cells exposed to DSS.

Discussion

IBD encompasses a range of inflammatory gastrointestinal disorders. There is substantial evidence to suggest that inflammation is the main component leading to impaired mucosal homeostasis [21]. Changes in the intestinal barrier function play an important role in IBD, and the loss of the integrity of the mucosal layer may cause diet/bacterial-derived molecules to trigger an uncontrollable inflammatory signal cascade [22,23]. DSS, one of the water-soluble, negatively charged bioreactive sulfated polysaccharides, has been widely used over the past decades to induce inflammation in experimental models [16]. The present study demonstrated that MMP13 and PRRX1 expression was upregulated in the NCM460 cells following exposure to DSS. Interference with PRRX1 transcription MMP13 exerted a cytoprotective effect against the DSS-induced inflammation and barrier dysfunction of NCM460 cells.

**Figure 4.** MMP13 overexpression attenuates the effects of PRRX1 knockdown on the barrier dysfunction of NCM460 cells challenged with DSS. (a and b) The expression of barrier dysfunction-related proteins, including ZO-1, occludin and claudin-1 was determined by Western blot analysis and reverse transcription-quantitative PCR. (c) The cellular permeability was evaluated by TEER. *P < 0.05, **P < 0.01 and ***P < 0.001. PRRX1, paired related homeobox 1; ZO-1, Zonula occludens-1.
The inflammatory response is the key factor for the progression of IBD, and elevated levels of inflammatory cytokines (TNF-α, IL-1β and IL-6) have been observed in active IBD and are associated with the severity of inflammation [7]. It is widely accepted that the aforementioned inflammatory factors contribute to the alteration of tight junctions and intestinal permeability [24]. The intestinal epithelium is composed of a layer of epithelial cells and is a crucial part of the intestinal mucosal barrier [25]. The function of the intestinal barrier is mediated by cell-cell junctions that link epithelial cells together into a structural and functional continuum, whose normal functional homeostasis can inhibit the entry of external antigens and incoming microorganisms into the body [26]. The destruction of these junctions can enhance intestinal permeability, which in turn triggers an inflammatory cascade in the colon. Therefore, epithelial dysfunction has been considered a hallmark of IBD [27]. ZO-1, occludin and claudin-1 are three crucial tight junction proteins, which are closely related to the maintenance of the physiological function of the intestinal barrier [8].

In recent years, an increasing number of scholars worldwide have devoted their efforts in exploring the important role of MMPs in controlling normal barrier function and regulating inflammation in the gut [28–30]. MMP13 is a member of a large family of zinc-dependent neutral endopeptidases [10]. Vizoso et al [11] revealed that MMP13 expression was significantly elevated in the mucosal samples of patients with IBD, and MMP-13 expression positively correlated with the applied histological inflammation score in IBD. The study by Rath et al [31] also demonstrated the enhanced expression of MMP13 in IBD. Of note, MMP13 can regulate the barrier function of the intestinal mucosal epithelium by activating TNF-α [32]. PRRX1 is a newly identified transcription factor that affects the expression of multiple genes related to inflammation [14]. PRRX1 was shown to be highly expressed in the mucosal tissues of patients with UC in the GSE87466 microarray (including 87 samples of UC and 21 normal samples). The data obtained in the present study suggested that DSS stimulation led to a notably elevated MMP13 and PRRX1 expression in human colon mucosal epithelial cells, which is in consistent with the findings of the aforementioned studies. Additionally, the JASPAR database predicted that PRRX1 could directly bind to the MMP13 promoter, which was verified by luciferase reporter and ChIP assays in the present study, suggesting that PRRX1 could directly bind to the MMP13 promoter in DSS-stimulated NCM460 cells. Furthermore, MMP13 overexpression attenuated the effects of PRRX1 knockdown on the inflammation and barrier function of NCM460 cells challenged with DSS.

Of course, our experiment has a limitation. In this study, we only discussed the effects and regulatory mechanism of PRRX1 and MMP13 in DSS-induced NCM460 cells, which is only an in vitro model that simplifies the events that occurs during DSS exposure in in vivo conditions. The further in vivo experiments will be performed in the future investigation to support the conclusion obtained in this study.

**Conclusion**

In conclusion, to the best of our knowledge, the present study is the first to investigate the effects of MMP13 and PRRX1 in the progression of IBD in DSS-stimulated cells. It was demonstrated that interference with PRRX1 transcription and MMP13 exerted a cytoprotective effect against the DSS-induced inflammation and barrier dysfunction of human colon mucosal epithelial cells. These findings provide new insight into the mechanisms underlying IBD and may thus provide a novel approach for the treatment of this disease.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This work was supported by S&T Program of Hebei (NO. H2019209241).
Availability of data and materials

The raw data supporting the conclusions of this article are available from the corresponding author on reasonable request.

References

[1] Cader M, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut. 2013;62(11): 1653–1664.
[2] Aleksandrova K, Romero-Mosquera B, Hernandez V. Diet, gut microbiome and epigenetics: emerging links with inflammatory bowel diseases and prospects for management and prevention. Nutrients. 2017;9 :962.
[3] Agilli M, Aydin F, Cayci T, et al. Assessment of active mucosal inflammation in IBD patients in clinical remission. J Gastrointestin Liver Dis. 2014;23(4): 462–463.
[4] Hildner K, Punkenburg E, Abendroth B, et al. Immunopathogenesis of IBD: batf as a key driver of disease activity. Dig Dis. 2016;34(Suppl. 1): 40–47.
[5] Ng S, Shi H, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114): 2769–2778.
[6] Hoivik M, Moun B, Solberg I, et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN study. Gut. 2013;62 (3): 368–375.
[7] Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol. 1999;34(1): 66–74.
[8] Wu X, Huang X, Chen R, et al. Paenilolinor prevents intestinal barrier disruption and inhibits Lipopolysaccharide (LPS)-Induced inflammation in Caco-2 cell monolayers. Inflammation. 2019;42(6): 2215–2225.
[9] Ailenberg M, Setton M. Effect of a matrix metalloproteinase sequestering biomaterial on Caco-2 epithelial cell barrier integrity in vitro. Acta Biomater. 2009;5 (6): 1898–1904.
[10] Nagase H, Jf W Jr. Matrix metalloproteinases. J Biol Chem. 1999;274(31): 21491–21494.
[11] Vizoso F, González L, Corte M, et al. Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease. Scand J Gastroenterol. 2006;41 (9): 1050–1055.
[12] Kern M, Argao E, Birkenmeier E, et al. Genomic organization and chromosome localization of the murine homeobox gene Pmx. Genomics. 1994;19(2): 334–340.
[13] Yang R, Liu Y, Wang Y, et al. Low PRRX1 expression and high ZEB1 expression are significantly correlated with epithelial-mesenchymal transition and tumor angiogenesis in non-small cell lung cancer. Medicine (Baltimore). 2021;100(4): e24472.
[14] Dankel S, Grytten E, Bjune J, et al. COL6A3 expression in adipose tissue cells is associated with levels of the homeobox transcription factor PRRX1. Sci Rep. 2020;10(1): 20164.
[15] Barthà A, Györffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci 2021 22 . 2622 .
[16] Ding A, Wen X. Dandelion root extract protects NCM460 colonic cells and relieves experimental mouse colitis. J Nat Med. 2018;72(4): 857–866.
[17] Wang Y, Chen H, Chen Q, et al. The protective mechanism of CAY10683 on intestinal mucosal barrier in acute liver failure through LPS/TLR4/MyD88 pathway. Mediators Inflamm. 2018;2018: 7859601.
[18] Wang J, Fan Z, Li J, et al. Transcription factor specificity protein 1-mediated Serine/threonine kinase 39 upregulation promotes the proliferation, migration, invasion and epithelial-mesenchymal transition of hepatocellular carcinoma cells by activating the transforming growth factor-beta1 /Smad2/3 pathway. Bioengineered. 2021;12(1): 3566–3577.
[19] Xing J, Jia Z, Xu Y, et al. KLF9 (Kruppel Like Factor 9) induced PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3) downregulation inhibits the proliferation, metastasis and aerobic glycolysis of cutaneous squamous cell carcinoma cells. Bioengineered. 2021;12(1): 7563–7576.
[20] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4): 402–408.
[21] Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc. 2019;94(1): 155–165.
[22] Lu M, Ji J, Jiang Y, et al. An inhibitor of the Keap1-Nrf2 protein-protein interaction protects NCM460 colonic cells and alleviates experimental colitis. Sci Rep. 2016;6(1): 26585.
[23] Gamah M, Alahdal M, Zhang Y, et al. High-altitude hypoxia exacerbates dextran sulfate sodium (DSS)-induced colitis by upregulating Th1 and Th17 lymphocytes. Bioengineered. 2021;12(1): 7985–7994.
[24] Reinecker H, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol. 1993;94: 174–181.
[25] Gadaleta R, van Erpucum K, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60(4): 463–472.
[26] Hooper L, Bryant L, Falk P, et al. Host-microbial symbiosis in the mammalian intestine: exploring an internal ecosystem. BioEssays. 1998;20(4): 336–343.
[27] Citalán-Madrid A, Vargas-Robles H, García-Ponce A, et al. Cortactin deficiency causes increased RhoA/
ROCK1-dependent actomyosin contractility, intestinal epithelial barrier dysfunction, and disproportionately severe DSS-induced colitis. Mucosal Immunol. 2017;10(5): 1237–1247.

[28] Giuffrida P, Biancheri P, MacDonald TT. Proteases and small intestinal barrier function in health and disease. Curr Opin Gastroenterol. 2014;30(2): 147–153.

[29] Medina C, Radomski M. Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther. 2006;318(3): 933–938.

[30] Vaalamo M, Karjalainen-Lindsberg M, Puolakkainen P, et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol. 1998;152(4): 1005–1014.

[31] Rath T, Roderfeld M, Graf J, et al. Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis. 2006;12(11): 1025–1035.

[32] Vandenbroucke R, Dejonckheere E, Van Hauwermeiren F, et al. Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol Med. 2013;5(7): 1000–1016.